Phys.OrgTechnique to fine-tune two-component biological sensorsPhys.OrgTabor and Landry suggest this system could be coupled to pathways under development by a colleague at MIT, synthetic biologist Chris Voigt, and his lab to engineer soil bacteria tha… Continue reading
SMA News TodayGene Therapy in Limelight on Novartis Deal: 3 Stocks in FocusZacks.comPer the agreement, Novartis will pay $8.7 billion for the buyout of this clinical stage gene therapy company. AveXis lead product candidate, AVXS-101, is being evaluate… Continue reading
SMA News TodayGene Therapy in Limelight on Novartis Deal: 3 Stocks in FocusZacks.comPer the agreement, Novartis will pay $8.7 billion for the buyout of this clinical stage gene therapy company. AveXis lead product candidate, AVXS-101, is being evaluate… Continue reading
FierceBiotech |
Pfizer puts Bamboo’s muscular dystrophy gene therapy to the test
FierceBiotech At least two other trials of DMD gene therapies are also ongoing in the U.S., both involving candidates developed at Nationwide Children’s Hospital (NCH) and partnered by Sarepta. One of the two phase 1/2 trials is based on delivery of a … |
Xconomy |
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts
Xconomy Elsewhere this week, Novartis bet heavily on gene therapy while GlaxoSmithKline asked out, the Theranos saga rolled on, and a few biotechs to go public since 2015 crashed and burned. Let’s round it all up. CANCER HEADLINES. —This year’s American … |
Xconomy |
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts
Xconomy Elsewhere this week, Novartis bet heavily on gene therapy while GlaxoSmithKline asked out, the Theranos saga rolled on, and a few biotechs to go public since 2015 crashed and burned. Let’s round it all up. CANCER HEADLINES. —This year’s American … |